A drug called AM630 that blocks a specific receptor in the body increased the activity of an important muscle enzyme in obese rats, suggesting it may help restore how muscles burn fat for energy. According to Gram Research analysis of this 2026 study with 30 rats, AM630 boosted citrate synthase activity in muscle tissue, a key marker of the muscle’s ability to produce energy efficiently.
Researchers tested a drug called AM630 on obese rats to see if it could improve how their muscles work. The drug targets a system in the body called the cannabinoid receptor 2, which affects how the body uses energy. According to Gram Research analysis, AM630 increased the activity of an important muscle enzyme and changed how muscles process fat for energy. The findings suggest that targeting this receptor system might help restore muscle health in people with obesity, though more research in humans is needed to confirm these results.
Key Statistics
A 2026 study of 30 obese rats found that the drug AM630 increased citrate synthase activity in the red gastrocnemius muscle, an enzyme critical for producing energy from fat.
In a 2026 animal study, AM630 altered multiple energy metabolism markers in the soleus muscle, including increasing phosphorylated 4EBP1 and decreasing PDK4 messenger RNA levels.
Research with 30 rats showed that when muscle samples from AM630-treated animals were exposed to adiponectin, they increased PGCl-α expression, a marker related to mitochondrial content and energy production capacity.
The Quick Take
- What they studied: Whether a drug that blocks a specific receptor in the body could improve how muscles work and burn energy in obese animals.
- Who participated: 30 male rats that were made obese by feeding them a high-fat diet for 9 weeks. The rats were then divided into three groups: one receiving no treatment, one receiving the drug AM630, and one receiving a different drug called AM1241.
- Key finding: The drug AM630 increased the activity of citrate synthase, an enzyme that helps muscles produce energy from fat. This suggests the drug may help restore muscle function in obesity.
- What it means for you: This early-stage research suggests a potential new treatment approach for obesity-related muscle problems. However, this was tested only in rats, so it’s too early to know if it will work in humans. Anyone interested in obesity treatment should continue following their doctor’s current recommendations.
The Research Details
Scientists used 30 male rats and first made them obese by feeding them a high-fat diet for 9 weeks. Then they divided the rats into three equal groups. One group received no treatment, one received daily injections of AM630 (a drug that blocks a specific receptor), and one received injections of AM1241 (a drug that activates the same receptor). This continued for 6 more weeks. The researchers then examined the rats’ muscles to measure enzyme activity and look at genetic markers related to energy production and fat burning. They also tested how the muscles responded to a protein called adiponectin, which is involved in metabolism.
This research design allowed scientists to compare how blocking versus activating the cannabinoid receptor 2 affects muscle metabolism. By testing both approaches, they could understand which direction might be more helpful. Testing in animals first is a standard step before human trials because it helps identify potential benefits and safety concerns.
This was a controlled laboratory study with a clear comparison between treatment groups, which is a solid research design. However, the sample size was small (30 rats total), and results from animal studies don’t always translate to humans. The study measured multiple markers of muscle function, which strengthens the findings. The research was published in a peer-reviewed journal, meaning other experts reviewed it before publication.
What the Results Show
AM630 increased the activity of citrate synthase in the red gastrocnemius muscle, which is important because this enzyme helps muscles produce energy from fat. In the soleus muscle, AM630 also changed several markers related to protein production and energy metabolism. Specifically, it increased a marker called phosphorylated 4EBP1, decreased a marker called phosphorylated AMPKα, and reduced PDK4 messenger RNA. These changes suggest the drug altered how the muscle processes energy. The other drug tested, AM1241, produced some similar effects but in different muscle types, indicating that how these drugs work depends on the specific muscle being studied.
When researchers exposed muscle samples to adiponectin (a protein that helps regulate metabolism), interesting differences emerged between treated and untreated muscles. In control animals, adiponectin reduced 4EBP1 activation, but in AM630-treated animals, adiponectin actually increased PGCl-α, a marker related to mitochondrial content. Both drugs reduced PGCl-α in the EDL muscle, suggesting they may affect mitochondrial function differently depending on the muscle type. These secondary findings highlight that the effects of these drugs are complex and vary across different muscle tissues.
Previous research showed that activating the cannabinoid receptor 2 could reduce body weight and increase overall energy expenditure in obese animals. This new study adds important detail by showing that blocking this receptor (with AM630) may specifically improve how muscles produce energy at the cellular level. The findings suggest that the relationship between this receptor system and muscle metabolism is more complicated than previously thought, with different effects in different muscle types.
This study was conducted only in rats, so results may not apply to humans. The sample size was relatively small (10 rats per group), which limits how confident we can be in the findings. The study measured enzyme activity and genetic markers but didn’t measure actual weight loss or overall fitness improvements. The drugs were given by injection rather than by mouth, which isn’t how medications are typically given to people. Finally, the study didn’t examine potential side effects or long-term safety of these treatments.
The Bottom Line
This research is preliminary and conducted only in animals. It should not be used to guide treatment decisions. Current evidence-based approaches for obesity include lifestyle changes (diet and exercise), behavioral therapy, and medications approved by regulatory agencies. Anyone with obesity should consult their healthcare provider about proven treatment options. This research may eventually lead to new treatments, but that would require additional studies in humans first.
Researchers studying obesity and muscle metabolism should pay attention to these findings as they may guide future drug development. People with obesity may find this interesting as a potential future treatment direction, but should not expect immediate clinical applications. Healthcare providers treating obesity should be aware of emerging research but should continue recommending current evidence-based treatments.
This is very early-stage research. Even if these results hold up in additional animal studies, it typically takes 5 to 10 years of research before a new drug could be tested in humans and potentially approved for use. People should not expect this treatment to become available soon.
Frequently Asked Questions
Can I take AM630 to help with obesity and muscle problems?
AM630 is not approved for human use and has only been tested in rats. This research is preliminary. Current proven treatments for obesity include diet, exercise, and FDA-approved medications. Talk to your doctor about options that are safe and effective for you.
How does blocking the cannabinoid receptor 2 help muscles work better?
The drug AM630 increased citrate synthase, an enzyme that helps muscles produce energy from fat. This suggests blocking this receptor may restore the muscle’s ability to burn fat efficiently, though the exact mechanisms are still being studied.
Why was this study done in rats instead of people?
Animal studies are the standard first step in drug research because they help identify potential benefits and safety concerns before testing in humans. If results are promising, researchers then design human trials, which typically take several years.
When will this treatment be available for people?
This is very early research. Even if animal studies continue to show promise, it typically takes 5 to 10 years of additional research before a new drug could be tested in humans and potentially approved for medical use.
Does this mean I should stop my current obesity treatment and wait for AM630?
No. Continue following your doctor’s current treatment plan. This research is preliminary and not yet applicable to humans. Proven treatments like exercise, healthy eating, and approved medications remain your best options for managing obesity.
Want to Apply This Research?
- Track daily physical activity and muscle-related fitness metrics (like how long you can walk or climb stairs) to monitor changes in muscle function over time, which would be relevant if similar treatments become available.
- Use the app to set and monitor goals for regular strength training and aerobic exercise, since current evidence shows these activities improve muscle metabolism and energy use in people with obesity.
- Log weekly measurements of energy levels, exercise capacity, and body composition changes to establish a baseline and track progress with current obesity treatments while staying informed about emerging research.
This research was conducted in rats and has not been tested in humans. AM630 is not approved for human use and should not be used outside of research settings. This article is for educational purposes only and should not be used to make medical decisions. Anyone with obesity should consult with their healthcare provider about proven, evidence-based treatment options. Do not stop or change any current obesity treatments based on this preliminary research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.